Evidence map›Paper›PMID 24868011›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2014

Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4.

Elham Asgari, Conrad A Farrar, Nicholas Lynch, Youssif M Ali, Silke Roscher, Cordula Stover, Wuding Zhou, Wilhelm J Schwaeble, Steven H Sacks

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 86 citations in OpenAlex.

  1. Review
  2. Collectin-11 regulates osteoclastogenesis and bone maintenance via a complement-dependent mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Complement Inhibition in Kidney Transplantation: Where Are We Now?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Elham AsgariMedical Research Council Centre for Transplantation, King's College London, Guy's Campus, London, UK; and asgelham@gmail.com.
Conrad A FarrarMedical Research Council Centre for Transplantation, King's College London, Guy's Campus, London, UK; and.
Nicholas LynchDepartment of Infection, Immunity, and Inflammation, University of Leicester, Leicester, UK.
Youssif M AliDepartment of Infection, Immunity, and Inflammation, University of Leicester, Leicester, UK.
Silke RoscherDepartment of Infection, Immunity, and Inflammation, University of Leicester, Leicester, UK.
Cordula StoverDepartment of Infection, Immunity, and Inflammation, University of Leicester, Leicester, UK.
Wuding ZhouMedical Research Council Centre for Transplantation, King's College London, Guy's Campus, London, UK; and.
Wilhelm J SchwaebleDepartment of Infection, Immunity, and Inflammation, University of Leicester, Leicester, UK.
Steven H SacksMedical Research Council Centre for Transplantation, King's College London, Guy's Campus, London, UK; and.
University of Leicester · GBKing's College London · GB

Funding

Medical Research Council G0501425Medical Research Council G0600892Medical Research Council G0700859Medical Research Council G0801952Medical Research Council G1000191Medical Research Council MR/J006742/1Wellcome Trust 079772
6 · The paper itself

Abstract

Mannan-binding lectin-associated serine protease 2 (MASP-2) has been described as the essential enzyme for the lectin pathway (LP) of complement activation. Since there is strong published evidence indicating that complement activation via the LP critically contributes to ischemia reperfusion (IR) injury, we assessed the effect of MASP-2 deficiency in an isogenic mouse model of renal transplantation. The experimental transplantation model used included nephrectomy of the remaining native kidney at d 5 post-transplantation. While wild-type (WT) kidneys grafted into WT recipients (n=7) developed acute renal failure (control group), WT grafts transplanted into MASP-2-deficient recipients (n=7) showed significantly better kidney function, less C3 deposition, and less IR injury. In the absence of donor or recipient complement C4 (n=7), the WT to WT phenotype was preserved, indicating that the MASP-2-mediated damage was independent of C4 activation. This C4-bypass MASP-2 activity was confirmed in mice deficient for both MASP-2 and C4 (n=7), where the protection from postoperative acute renal failure was no greater than in mice with MASP-2 deficiency alone. Our study highlights the role of LP activation in renal IR injury and indicates that injury occurs through MASP-2-dependent activation events independent of C4.

Indexed as

Kidney TransplantationPostoperative ComplicationsAnimalsBlood Urea NitrogenComplement C3dComplement C4FemaleImmunoenzyme TechniquesKidney DiseasesMaleMannose-Binding Protein-Associated Serine ProteasesMiceMice, Inbred C57BLMice, KnockoutNephrectomyReperfusion InjuryC4b protein, mouseComplement C3dComplement C4Mannose-Binding Protein-Associated Serine ProteasesMASP-2 protein, mouseinflammationkidney transplantation

Identifiers

PMID24868011
PMCPMC5184842
OpenAlexW2064409684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.